Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: J Thorac Oncol. 2022 Jun 24;17(9):1109–1121. doi: 10.1016/j.jtho.2022.06.004

Figure 2. Illustration of preferential POU2F3 expression in SCLC with low or absent expression of standard NE markers.

Figure 2.

Case in the left panel illustrates a NE-high SCLC (NE-score = 229) showing strong diffuse expression of all conventional NE markers and TTF-1, and negative POU2F3. Other cases are examples of NE-low (Case IDs 23 and 25) or entirely negative (Case ID 29) SCLC with robust expression of POU2F3.

Abbreviations: CHRA chromogranin A, NE neuroendocrine, SYN synaptophysin